Internal Medicine, Universidad Libre, Cali, Colombia.
Arthritis and Rheumatology Clinic, Centro Médico Imbanaco, Cali, Colombia.
Rheumatol Int. 2020 Mar;40(3):489-497. doi: 10.1007/s00296-019-04453-y. Epub 2019 Oct 10.
Systemic sclerosis (SSc) is a rare immune-mediated vasculopathy characterized by fibrosis of the skin and internal organs. Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the GLA gene producing α-galactosidase-A enzyme (α-Gal A) deficiency. Being a systemic disease, cardiac involvement in FD has a high mortality rate due to heart failure and arrhythmia. The coexistence of these two entities has not been reported previously. We describe the case of a female patient with limited SSc (lcSSc), a diagnosis based on the presence of sclerodactyly, Raynaud phenomenon, microvascular involvement, and positive anti-centromere antibodies. On follow-up, she developed chest pain, a second-degree A-V block, and restrictive cardiomyopathy (without cardiovascular risk factors). Although heart involvement is common in these two entities, the abnormal thickening of lateral and inferior wall, the infiltration pattern and the conduction system disorders presented herein are more characteristic in a heterozygous female with a cardiac variant of FD. The diagnosis of FD was confirmed with high globotriaosylsphingosine (Lyso-Gb3) levels and identification of GLA gene mutation. The patient was treated with enzymatic replacement (agalsidase alpha) following mild improvement in ventricular mass at 6th month, without clinical deterioration. The related literature on SSc associated with FD is also reviewed.
系统性硬化症(SSc)是一种罕见的免疫介导性血管病变,其特征为皮肤和内脏器官纤维化。法布里病(FD)是一种 X 连锁溶酶体贮积病,由 GLA 基因突变导致α-半乳糖苷酶-A 酶(α-Gal A)缺乏引起。由于 FD 是一种全身性疾病,心脏受累的死亡率很高,原因是心力衰竭和心律失常。这两种疾病同时存在以前没有报道过。我们描述了一例局限性系统性硬化症(lcSSc)女性患者的病例,该患者的诊断基于硬皮病、雷诺现象、微血管受累和阳性抗着丝点抗体的存在。随访时,她出现胸痛、二度房室传导阻滞和限制性心肌病(无心血管危险因素)。尽管这两种疾病都常见心脏受累,但此处出现的外侧和下壁异常增厚、浸润模式和传导系统障碍在 FD 的心脏变异型杂合子女性中更具特征性。通过检测高 globotriaosylsphingosine(Lyso-Gb3)水平和鉴定 GLA 基因突变,确诊 FD。该患者接受了酶替代治疗(agalsidase alpha),6 个月时心室质量有轻度改善,无临床恶化。还对与 FD 相关的 SSc 的相关文献进行了综述。